VANCOUVER, BC, October 5, 2022 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce the appointment of Jacqueline Tucker as Chief Financial Officer (CFO) from October 1, 2022.
Ms. Tucker is President of JM Tucker Professional Corporation, which provides CFO advisory services to public companies. She is currently CFO of True North Gems, Inc. and East Africa Metals, Inc. She is also part of Kadestone Capital Corp. and Ikänik Farms, Inc. (Canada) boards. She is a member of the Institute of Chartered Accountants of alberta and Chartered Professional Accountants of Ontario.
Ms. Tucker has an exceptional track record of financial leadership, having held senior positions in many leading Canadian companies, including Chief Financial Officer of Fact Corp., Chief Financial Officer of Canamax Energy Ltd., Financial Director of True North Gems, Inc., Chief Financial Officer and Director of Canadian Imperial Venture Corp. and CEO, CFO and Director at IGC Resources, Inc. Ms. Tucker is a Fellow of the Institute of Chartered Accountants of British Columbia. She earned an undergraduate degree from the University of Western Ontario.
Mrs. Tucker replaces John Gretchen, who will continue to act as a consultant for the Company. The Asep Inc. management team thanks Ms. Gretchen for her outstanding service during her tenure as Chief Financial Officer and looks forward to her expertise and leadership.
Chief Operating Officer of Asep Inc. Tim Murphy said, “Jacqueline is a seasoned professional who brings decades of public procurement and accounting experience to the team. We look forward to working with her as the company continues to grow and prepare for market.
ABOUT ASEP MEDICAL HOLDINGS INC.
Asep Medical Inc. (asepmedical.com) is dedicated to addressing antibiotic failure by developing new solutions for significant unmet medical needs. The company is a consolidation of two existing private companies (Sepset Biosciences Inc. and ABT Innovations Inc.) which are both in the advanced development of the two proprietary diagnostic tools, enabling the early and rapid identification of severe sepsis as well as broad-spectrum therapies. agents for combating multidrug resistant biofilm infections.
Sepset Biosciences Inc. (septet.ca) is developing diagnostic technology that involves a patient’s gene expression signature that predicts severe sepsis, one of the important diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for almost 20% of all deaths on the planet. The SepsetEmergency room is a blood-based gene expression test that is simple to perform and results are obtained in approximately one hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in that it can diagnose severe sepsis within 1-2 hours of first clinical presentation (i.e. in the emergency room), while other diagnostics provide a diagnosis only after 24 to 36 hours. Asep Inc. believes this will enable physicians to make critical early decisions about appropriate treatments and reduce overall morbidity and mortality from sepsis.
ABT Innovations Inc. (abtinnovations.ca) peptide technology covers a wide range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, otolaryngology, sinusitis, orthopedics, etc.), anti-inflammatories, anti-infective immunomodulators and vaccine adjuvants.
FORWARD-LOOKING STATEMENTS –
This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities laws. Forward-looking statements are often characterized by words such as “expects”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “expects”, ” believes”, “may”, “will”, “potential”, “proposed”, “positioned” and other similar words, or statements that certain events or conditions “may” or “will occur”. These statements include, but are not limited to, the successful completion of clinical testing of our Sepsis diagnostic test and its anticipated filing for regulatory approval; and conducting preclinical studies on our lead drug, in the hope that this will lead to accelerated clinical trials. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management as of the date they are made and are subject to various risks (including the risk factors identified in Asep Medical Inc.’s prospectus dated November 9, 2021) available for review under the company profile at www.sedar.com and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. applicable expressly so requires.
SOURCEASEP Medical Holdings Inc.